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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of this review is to assess and compare the diagnostic accuracy of ultrasound assessment of fetal growth and
placental biomarkers alone and in any combination used after 24 weeks of pregnancy in the identification of placental dysfunction
as evidenced by either stillbirth or born small-for-gestational age (SGA). Accuracy is described by the proportion of fetuses who are
subsequently stillborn or who have a SGA baby detected by a positive test result (the presence of placental dysfunction) (sensitivity)
and by the proportion of fetuses that have an uncomplicated pregnancy following a negative index tests result (absence of placental
dysfunction) (specificity).
Wewill investigate the effect of clinical (patient and test characteristics) andmethodological factors (study design, threshold used todefine
SGA) on test performance. The clinical factors include patient group (low-risk or high-risk pregnancies), gestation at measurement,
ethnicity, maternal age and method of testing. With regard to methodological variation, studies may include an intervention (delivery
or additional fetal surveillance for test positive cases) which will impact on the outcome; therefore we will assess whether this is a source
of heterogeneity.
B A C K G R O U N D
Stillbirth affects 2.6 million pregnancies worldwide each year
(Cousens 2011). Although the majority of cases occur in low- and
middle-income countries, stillbirth places a significant burden in
high-income countries (HICs) with the UK and the US report-
ing rates above the mean for HICs (Flenady 2011b). In HICs,
the most frequently reported association with stillbirth is placen-
tal dysfunction, which may be clinically evident as fetal growth
restriction (FGR), small-for-gestational-age (SGA) infants, pla-
cental abruption or hypertensive disorders of pregnancy. Placen-
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tal abnormalities are noted in 11% to 65% of stillbirths (Ptacek
2014). Identification of FGR is difficult in utero and even after
birth, with SGA being most commonly used as a surrogate mea-
sure (Worton 2014). The degree of SGA is associated with the
likelihood of FGR; 30% of infants with a birthweight <10th cen-
tile are thought to be FGR, while 70% of infants with a birth-
weight < third centile are thought to be FGR. Critically, SGA
is the most significant antenatal risk factor for a stillborn infant
(Flenady 2011a; Gardosi 2013; McCowan 2007). Importantly,
correct identification of SGA infants is associated with a reduction
in the perinatal mortality rate (Gardosi 2013). However, currently
used tests, such as measurement of symphysis-fundal height, have
a low reported sensitivity and specificity for the identification of
SGA infants (RCOG 2014).
Due to the importance of the placenta there is growing interest
in antenatal placental evaluation in an attempt to identify preg-
nancies at increased risk of stillbirth or fetal compromise (Heazell
2015a). A systematic review of biochemical tests of placental func-
tion found insufficient evidence to conclude whether these inter-
ventions had any effect on perinatal mortality or fetal compromise
(Heazell 2015b). In contrast, a single trial of placental grading
assessed by ultrasound demonstrated reduced perinatal mortality
(Proud 1987). Systematic reviews of other methods employed to
identify fetal compromise such as ultrasound assessment of fe-
tal growth or umbilical artery Doppler (measurement of blood
flow through the umbilical artery) in late pregnancy have also
found insufficient evidence to conclude whether these interven-
tions reduce perinatal mortality in a low-risk maternity popula-
tion (Alfirevic 2015; Bricker 2015), although both are effective
in women deemed to be at high risk of pregnancy complications
(Alfirevic 2013). The efficacy of umbilical artery Doppler in high-
risk populations may be due to its prognostic accuracy; a system-
atic review found this test predicted SGA infants with a positive
likelihood ratio of 3.76 and stillbirth with a positive likelihood
ratio of 4.37 (Morris 2011).
Two components are necessary to reduce perinatal mortality and
minimise unwarranted intervention. Firstly, the test must accu-
rately identify fetal compromise and secondly, the intervention
must be effective in preventing the adverse outcome. There is now
strong evidence that planned delivery (by induction of labour) af-
ter 37 weeks of pregnancy is associated with a reduction in peri-
natal mortality (Stock 2012). Therefore, the most accurate test to
identify fetal compromise needs to be determined so that it may
be combined with planned delivery.
Target condition being diagnosed
The target condition of interest is placental dysfunction - which
describes the condition in which the placenta does not meet the
demands of the fetus (Heazell 2015a). As with other organ dys-
function, there are multiple pathways that can result in placental
dysfunction including vascular, inflammatory, infective and ge-
netic disorders. These various processes may lead to changes in
placental structure and/or function that may lead to two clinical
outcomes i) stillbirth or ii) an SGA infant. As placental dysfunc-
tion cannot easily be quantified this review will use these two clin-
ical outcomes as the target conditions of interest.
Index test(s)
This review will evaluate tests used in late pregnancy (after 24
weeks) to identify pregnancies that have placental dysfunction in-
forming decisions to continue with the pregnancy or institute in-
tervention. The tests to be evaluated include assessment of pla-
cental structure and biochemical function by ultrasound scan or
measurement of placental products in maternal blood (plasma or
serum) or urine.
Biochemical tests of placental function measure placental prod-
ucts (proteins, peptides,metabolites) inmaternal biofluids (serum,
plasma, urine); it is hypothesised that levels of such products inma-
ternal fluids reflect endocrine and metabolic functions of the pla-
centa.Many placental products can be detected inmaternal bioflu-
ids including protein hormones: human chorionic gonadotrophin
(hCG), human placental lactogen (hPL), human placental growth
hormone (hPGH), placental growth factor (PlGF), placental pro-
tein-13 (PP-13), pregnancy specific glycoproteins and steroid hor-
mones including oestrogens and progesterone with their related
metabolites. Ultrasonography has been used to measure the size,
shape and echotexture of the placenta; the majority of such stud-
ies have used 2D ultrasound to evaluate placental morphology,
although newer studies have utilised 3D techniques. We have not
included umbilical artery Doppler in this analysis as a systematic
review and meta-analysis has been conducted (Morris 2011).
Clinical pathway
Antenatal care differs between countries, the clinical pathway de-
scribed here applies to the UK and follows guidance from the
Royal College of Obstetricians and Gynaecologists (RCOG 2014)
and the National Institute for Health and Social Care Excellence
(NICE 2008).
Prior test(s)
Currently, in the UK women are grouped into high risk and low
risk for SGA in early pregnancy at the booking-in visit by assessing
a woman’s past medical history, obstetric history and risk factors
for an SGA infant (RCOG2014). All woman are offered screening
for Down’s syndrome (which is currently based on measurement
of nuchal translucency by ultrasound scan and measurement of
serum analytes between 11 and 13+6 weeks of pregnancy) and for
fetal anomaly (by ultrasound scan from 18 to 20+6 weeks).
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In clinical practice, placental dysfunction is suspected by identi-
fication of an SGA infant. However, subsequent testing for SGA
will depend upon the risk status of the woman (RCOG 2014).
The National Institute for Health and Care Excellence do not rec-
ommend routine measurement of fetal growth by ultrasound scan
in late pregnancy (NICE 2008). Fetal growth is assessed in women
deemed to be at low risk of an SGA infant bymeasurement of sym-
physis-fundal height with a tape measure (RCOG 2014). Women
at increased risk of SGA are recommended to have a uterine artery
Doppler (to assess blood flow through both uterine arteries) at
20 weeks’ gestation and regular scans to measure fetal biometry
with assessment of liquor volume and umbilical artery Doppler.
Umbilical artery Doppler is the most frequently employed test to
predict fetal outcome; the relationship between umbilical artery
Doppler indices and placental function is not clear. In addition to
recommendations for the diagnosis and management of an SGA
fetus, ultrasound assessment of fetal growth, liquor volume and
umbilical artery Doppler are recommended following maternal
presentation with reduced fetal movements, as this may be a symp-
tom of placental insufficiency (RCOG 2011). The current clinical
pathway is shown in Figure 1.
Figure 1. Current clinical pathway and three proposed uses of a placental function test. Currently, women
are screened for a small for gestational age fetus (as a proxy for placental dysfunction) using symphysis-fundal
height and maternal awareness of fetal movements. Women deemed to be an increased risk are screened
using ultrasound measurement of fetal biometry. We propose three different clinical pathways for placental
function tests. Firstly, they could be used as an additional test when Doppler measurements were normal.
They could be used in combination with currently used tests and finally they could be used as a triage test to
differentiate infants who are constitutionally small from those with placental dysfunction. Although treatment
decisions would be tailored to individual cases, a positive test would be expected to lead to increased
surveillance or intervention (planned delivery) and negative test would lead to continuing with the pregnancy.
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When an SGA infant is identified by tests, clinical management
is dependent upon gestation. At ≥ 37 weeks delivery is offered
(RCOG 2014). Prior to this gestation, fetal compromise is assess
by measurement of Doppler waveforms primarily in the umbilical
artery, but may also include the middle cerebral artery and duc-
tus venosus. Delivery is recommended when fetal compromise is
identified (RCOG 2014).
There are currently no routinely used measures of placental func-
tion after 16 weeks of pregnancy. There is evidence that mea-
surement of placental analytes as part of screening for aneuploidy
may identify fetuses at high risk of early-onset FGR (Smith 2002;
Smith 2006). Assessment of these analytes is incorporated into the
current clinical pathway (RCOG 2014); women with low preg-
nancy-associated plasma protein A (PAPP-A) levels are managed
as high risk for SGA. Therefore, we wish to focus on placental tests
performed in late pregnancy (after 24 weeks’ gestation).
Role of index test(s)
Due to the established use of ultrasound in obstetric practice, we
envisage that additional tests of placental function would most
likely be added to an ultrasound measurement of fetal size rather
than replacing it (Figure 1); this is certainly true of the interven-
tion trials of placental assessment (by biochemical tests) that have
been conducted (Duenholter 1976; Heazell 2013; Sharf 1984).
It is hypothesised the addition of a placental function test to an
ultrasound scan would improve identification of an SGA infant
and consequently focus intervention on pregnancies at greatest
risk of stillbirth or fetal compromise, thereby reducing the bur-
den of perinatal mortality and morbidity. It is also possible that a
placental function test could be used to triage infants who were
SGA to identify which were constitutionally small and which had
placental dysfunction. This would allow the pregnancy to con-
tinue in otherwise healthy constitutionally small infants, reducing
unnecessary intervention. If placental function tests were used in
this way a false positive test would lead to increased intervention,
either surveillance or delivery, and a false negative test would al-
low a potentially compromised baby to remain in utero without
increased surveillance. From the perspective of reducing perina-
tal mortality and morbidity, a false negative test would be more
harmful than a false positive test.
Alternative test(s)
Presently, there are no tests in widespread clinical use that directly
assess placental biochemical function.
Rationale
There are several tests of placental structure and function. System-
atic reviews of the measurement of biochemical placental factors
and the effectiveness of ultrasound in late pregnancy found that
few tests of placental structure or function have been evaluated in
robust intervention studies (Bricker 2015; Heazell 2015a). This
review aims to identify and evaluate tests of placental structure and
function, not restricted to those evaluated in intervention studies,
to determine which measurement(s) have the greatest diagnostic
accuracy for detection of placental dysfunction leading to stillbirth
and SGA. The most accurate test(s) can then be taken forward
into intervention studies to determine whether performing inves-
tigations can reduce perinatal morbidity or mortality.
O B J E C T I V E S
The primary objective of this review is to assess and compare the
diagnostic accuracy of ultrasound assessment of fetal growth and
placental biomarkers alone and in any combination used after 24
weeks of pregnancy in the identification of placental dysfunction
as evidenced by either stillbirth or born small-for-gestational age
(SGA). Accuracy is described by the proportion of fetuses who are
subsequently stillborn or who have a SGA baby detected by a pos-
itive test result (the presence of placental dysfunction) (sensitivity)
and by the proportion of fetuses that have an uncomplicated preg-
nancy following a negative index tests result (absence of placental
dysfunction) (specificity).
Secondary objectives
Wewill investigate the effect of clinical (patient and test character-
istics) and methodological factors (study design, threshold used to
define SGA) on test performance. The clinical factors include pa-
tient group (low-risk or high-risk pregnancies), gestation at mea-
surement, ethnicity, maternal age and method of testing. With
regard to methodological variation, studies may include an inter-
vention (delivery or additional fetal surveillance for test positive
cases) which will impact on the outcome; therefore we will assess
whether this is a source of heterogeneity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Presently, there are no effective interventions to reverse placental
dysfunction in utero. This means that once detected, an interven-
tion cannot be employed to reverse the small-for-gestational age
(SGA) phenotype following a positive test result. Delivery may be
indicated, although at earlier gestations this does not affect peri-
natal mortality (GRIT 2003). Therefore, we will include prospec-
tive and retrospective cross-sectional or cohort studies in which all
women receive one or more index tests and the outcome of their
pregnancy is known. Case-control studies will be excluded.
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Wewill include studies which measure index tests on one occasion
(cross-sectional design).
We will exclude studies where it is not possible to derive a 2 x 2
table of the number of true positives, false positives, false negatives
and true negatives, or studies that report preliminary experimental
findings, i.e. laboratory-based studies.
Participants
We will include studies of pregnant women after 24 weeks’ gesta-
tion that record relevant outcomes of pregnancy (live birth/still-
birth; SGA infant).
We will include studies of pregnant women of any reproductive
age, who are deemed to be low or high risk for complications (e.g.
who have pre-existing medical disorders or previous stillbirth) or
studies of mixed populations (of low and high risk for complica-
tions).
We will exclude pregnancies complicated by fetal abnormalities, as
they oftenhave a higher risk of stillbirth fromnon-placental causes.
We will exclude studies of women with multi-fetal pregnancies.
Index tests
Wewill include, but not be restricted to, the following index tests of
placental biochemical function, placental structure or assessment
of fetal biometry to identify an SGA infant:
• human placental lactogen (hPL) in maternal urine/blood;
• oestriol in maternal urine/blood;
• placental growth factor in maternal blood;
• ultrasound assessment of placental echogenicity;
• ultrasound assessment of fetal size.
With regard to biochemical tests, we will include assays that
have been performed using different techniques, including: im-
munoassay, enzyme-linked immunosorbent assay, chromatogra-
phy or point of care test in any combination and at any threshold
used to determine test positivity. Examples of current commer-
cially available tests are listed in Appendix 1.
Target conditions
The target conditions are stillbirth and delivery of a SGA infant
as clinical manifestations of placental dysfunction.
Reference standards
The outcome of pregnancy is considered as the reference standard.
A “positive” result will be either i) a stillbirth - an infant born
with no signs of life after 24 weeks’ gestation, or ii) a birthweight
classified as SGA. A “negative” result will be a live birth after
24 weeks’ gestation or a birthweight classified as appropriate for
gestational age.
The classification of SGA will be determined according to the
definition used in the study. Where possible the definition of an
infant with a birthweight≤ 10th centile using a customised birth-
weight calculator will be used (Clausson 2001). Where this is not
possible, the definition of SGA from the manuscript will be used
and recorded. If there are sufficient studies, the effects of different
definitions of SGA will be addressed as a potential source of het-
erogeneity.
Search methods for identification of studies
We will conduct a comprehensive search for existing systematic
reviews and primary studies relevant to the prevention of adverse
pregnancy outcome in women at increased risk of stillbirth by
detecting placental dysfunction. A scoping search was undertaken
in the bibliographic databasesMEDLINE,MEDLINE InProcess,
Embase, the Cochrane Library (CDSR, DARE, HTA, NHS EED
andCentral Register of ControlledTrials (CENTRAL) databases),
HTA and relevant web sites in order to identify existing reviews
and to gauge the nature and number of relevant studies to inform
the protocol.
Electronic searches
Wewill develop full search strategies based on the scoping searches,
expert advice, and consultation with the Cochrane Pregnancy and
Childbirth Group’s Information Specialist. They will include a
combinationof textwords and index terms.Methodological search
filters for diagnostic test accuracy will be avoided if possible as they
have been shown to miss relevant studies (Whiting 2011a). We
will not apply any language or date restrictions. We plan to search
the following sources:
• bibliographic databases - MEDLINE, MEDLINE In
Process and Embase via Ovid, Cochrane (Wiley) CENTRAL,
Science Citation Index (Web of Science), CINAHL (EBSCO)
with search strategies adapted for each database as required;
• ISRCTN Registry, UK Clinical Trials Gateway, WHO
International Clinical Trials Portal (ICTRP) and
ClinicalTrials.gov for ongoing studies;
• specialist abstract and conference proceeding resources
(British Library’s ZETOC and Web of Science Conference
Proceedings Citation Index).
A sample search strategy for MEDLINE is provided in Appendix
2.
Searching other resources
Wewill check citation lists of included studies and relevant reviews.
Wewill examine grey literature by searchingwebsites of companies
producing biochemical tests of placental function (Alere 2015;
Perkin Elmer 2015; Roche 2015). We will also undertake consul-
tation with experts in the field to access relevant unpublished data.
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Data collection and analysis
We will use the methods described in the Cochrane Hand-
book for Systematic Reviews of Diagnostic Test Accuracy (http://
dta.cochrane.org/handbook-dta-reviews).
Selection of studies
Two review authors will independently screen the titles and ab-
stracts of all studies identified by the search strategy. We will ob-
tain full-text versions of all potentially relevant studies. Two review
authors will independently assess studies for inclusion using pre-
specified inclusion criteria stated earlier.We will include studies of
pregnant women after 24weeks’ gestation that record relevant out-
comes of pregnancy (live birth/stillbirth; SGA infant), and present
data to construct a 2 x 2 table. We will resolve any disagreement
between the two review authors or by discussion with a third party
if needed. Reasons for study exclusion will be documented.
Data extraction and management
We will develop a customised form to ensure reproducible col-
lection of data items. Data collection will be piloted on five
manuscripts then reviewed by the review authors. Data will be
extracted independently by two review authors. We will resolve
discrepancies, where they occur, through discussion of if required
we will consult a third author drawing on clinical and method-
ological expertise in the team as appropriate to the content of the
query. We will extract characteristics of participants, index tests
or test combinations (including thresholds used), and details of
the reference standard in terms of pregnancy outcome (live birth
or stillbirth) and whether the infant was SGA. For studies that
report data at multiple thresholds for a test, we will extract a 2 x
2 table at each reported threshold. Where possible we will record
the frequency of obstetric intervention and infant admission to
neonatal intensive care. If reported, we will also record data on
outcomes including harms of testing, need for further testing, and
the effects of the test. We will not address women’s experiences of
testing, caregiver’s satisfaction with testing or economic evaluation
of testing as this is beyond the scope of this review.
We will attempt to contact the authors of included studies where
information considered key to assessment of methodological qual-
ity, investigation of heterogeneity, or completion of a 2 x 2 table is
unclear or missing. Studies published only as conference abstracts
will be followed up to identify whether a subsequent full paper
has been published.
Assessment of methodological quality
We will use the QUADAS-2 tool (Whiting 2011b) to assess the
risk of bias and applicability of included studies. We will tailor the
tool to our review question using the operational criteria detailed
in Appendix 3 to answer signalling questions and make the over-
all judgement of risk of bias and applicability concerns for each
domain of the tool. Two review authors will assess each included
study separately.We will resolve differences in assessment through
discussion and if required, by discussion with a third person. We
will assess each criteria in QUADAS-2 as “yes”, “no” or “unclear”
and summarise the results graphically or in tables (Appendix 3).
We will include all domains of QUADAS-2 assessment including
the time interval between testing and the outcome and any inter-
vention as these may alter the outcome. We have operationalised
the domains of the QUADAS-2 tool for the clinical context of
this review. For example, the domain concerning patient selection
was amended to ensure to allow appropriate exclusion criteria for
studies as placental function tests may be altered in women with
multiple pregnancies or with fetal abnormalities. However, other
criteria that would not be expected to alter tests of placental func-
tion (e.g. ethnicity, maternal age and income) would be inappro-
priate exclusions. It is essential that the sample is generalisable to
those in the review question, whereas studies may be restricted to
specific high-risk groups, e.g. maternal hypertension, which will
reduce the applicability. Studies may also use varied measures of
SGA (the reference standard); some of which are unrelated to ges-
tation, e.g. low birthweight (< 2.5 kg) which are less accurate and
may reduce study quality. Studies using a threshold which alters
with gender and gestation, e.g. individualised birthweight centile
will be rated more highly than those which do not.
Statistical analysis and data synthesis
For each test and type of biofluid, estimates of sensitivity and
specificity from each study will be plotted in receiver operating
characteristic (ROC) space and forest plots for preliminary inves-
tigations of the data. We anticipate that studies will use different
thresholds to dichotomise tests measured on a continuous scale.
Therefore, we plan to perform meta-analyses using the hierarchi-
cal summary ROC (HSROC) model (Rutter 2001) to estimate
SROC curves in RevMan 2014. Where a study reports multiple
thresholds for a test, we will select one threshold at random or the
threshold most frequently reported across studies so that only one
2 x 2 table is included in the meta-analysis. Methods that allow
joint synthesis of sensitivities and specificities at multiple thresh-
olds have been proposed, but are not used in practice and require
further evaluation before they can be used in Cochrane reviews
(Macaskill 2010). In separate analyses, where studies report com-
mon thresholds (e.g. for placental growth factor (PlGF) < 12 pg/
mL, Alere 2015), we will also estimate summary sensitivities and
specificities using functions of HSROC model parameters.
The main test comparison will be an indirect comparison pooling
all relevant studies that assessed at least one of the index tests. In
secondary analyses, wewill performdirect comparisons by restrict-
ing the analyses to only studies that have compared tests head-to-
head in the same study population. This analytical strategy was
adopted because of the paucity of comparative studies of diagnos-
tic accuracy (Takwoingi 2013). If we identify a large number of
tests, because of potential model complexity and additional num-
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ber of model parameters, we will limit the indirect comparison to
only those tests that provide adequate data, for example, at least
four studies. For direct comparisons, we will perform pair-wise
comparisons of tests. The test comparisons will be performed by
adding a covariate for test type to the HSROC model to estimate
differences in accuracy, threshold, and/or shape of SROC curves.
We will assess the statistical significance of differences between
tests using likelihood ratio tests comparing models with and with-
out the covariate terms. The NLMIXED procedure in the SAS
software package (version 9.3; SAS Institute, Cary, NC, USA) will
be used for meta-analyses.
Investigations of heterogeneity
Wewill initially examine heterogeneity between studies by visually
inspecting forest plots of sensitivity and specificity and summary
ROC plots. Where a sufficient number of studies assess the same
index test, potential sources of heterogeneity will be separated into
clinical (e.g. population studied, test type) and methodological
(as appropriate) sources. We will define whether these potential
sources of heterogeneity are dichotomous or continuous variables
and will perform appropriate meta-regression by adding the po-
tential source of heterogeneity as a covariate to the hierarchical
model. We will test for statistical difference in observed variation
by comparing shapes of the SROC curve for different variables
(e.g. type method, threshold used).
Sensitivity analyses
If there are sufficient studies of an individual index test, we will
perform the following sensitivity analyses by restricting analyses
to studies:
• without an intervention that may have altered outcome;
• at low risk of bias in each of the four domains of the
QUADAS-2 tool (Appendix 3);
• that specifically describe histological evidence of placental
insufficiency.
Assessment of reporting bias
We will not undertake any formal assessment of reporting bias in
our reviewdue to current uncertainty about how to assess reporting
bias in diagnostic test accuracy reviews, especially in the presence
of heterogeneity (Macaskill 2010).
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A P P E N D I C E S
Appendix 1. Examples of placental function tests available for diagnostic use (compiled 29th March
2016)
Placental growth factor (PlGF)
Triage PlGF (Alere, San Diego) - point of care fluorescence immunoassay (http://www.plgf.com/home/proposed-clinical-use-of-plgf/
alere-triage-plgf.html)
Elecsys™ Preeclampsia (sFlt-1 & PlGF) - automated immunoassay performed on Roche platform
(http://www.cobas.com/home/product/clinical-and-immunochemistry-testing/elecsys-preeclampsia-assays-sFlt-1-PlGF.html)
Oestriol (E3)
AutoDELFIA Unconjugated Estriol (Perkin Elmer) - automated fluorescence immunoassay performed on Perkin-Elmer platform. (
http://www.perkinelmer.co.uk/product/autodelfia-unconjugated-estriol-ue3-ki-b083-301)
Beckman Coulter - automated immunoassay performed on Beckman Coulter platform (https://www.beckmancoulter.com/wsrportal/
bibliography?docname=DS14764A%20Access%20Unconjugated%20Estriol%20US%20Data%20Sheet.pdf)
Elecsys™ Estradiol - automated immunoassay performed on Roche platform (http://www.cobas.com/content/dam/cobas˙com/pdf/
lists/parameter-list-swa.pdf)
Appendix 2. Example Search Strategy
Database: Ovid MEDLINE(R) 1946 to July Week 1 2015
Search Strategy:
--------------------------------------------------------------------------------
1 Placental insufficiency/
2 ((placenta$ or fetoplacental or uteroplacental) adj2 (insufficien$ or fail$ or function$)).ti,ab.
3 fetal movement/
4 fetal growth retardation/
5 ((reduc$ or decline$) adj2 fetal movement).ti,ab.
6 (stillborn or stillbirth).ti,ab.
7 Stillbirth/
8 ((fetal or intrauterine or intra-uterine) adj2 (growth or death$ or loss$)).ti,ab.
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9 IUGR.ti,ab.
10 (small adj2 gestational age).ti,ab.
11 ((neonatal or perinatal or fetal or birth$ or deliver$) adj2 outcome$).ti,ab.
12 fetal move$.ti,ab.
13 or/1-12
14 oestradiol.ti,ab.
15 estradiol.ti,ab.
16 exp Estradiol/
17 oestriol.ti,ab.
18 exp progesterone/
19 progesterone.ti,ab.
20 exp pregnenolone/
21 pregnenolone.ti,ab.
22 exp Chorionic Gonadotropin/
23 human chorionic gonadotrophin.ti,ab.
24 hCG.ti,ab.
25 placental lactogen/
26 hPL.ti,ab.
27 human placental lactogen.ti,ab.
28 human placental growth hormone.ti,ab.
29 placental protein 13.ti,ab.
30 placental growth factor.ti,ab.
31 plasma placental protein.ti,ab.
32 pregnancy specific glycoprotein$.ti,ab.
33 Pregnancy-Specific beta 1-glycoproteins/
34 schwangerschaft protein 1.ti,ab.
35 pregnancy specific beta 1-glycoprotein.ti,ab.
36 exp ultrasonography, Prenatal/
37 (sonograph$ or ultraso$).ti,ab.
38 Grannum grading.ti,ab.
39 biomarkers/
40 biomarker$ or marker$.ti,ab.
41 or/14-40
42 13 and 41
43 (animals not (humans and animals)).sh.
44 42 NOT 43
Appendix 3. QUADAS 2 tool for assessing methodological quality of included studies
Domain Signalling
question
Signalling
question
Signalling
question
Risk of bias Concerns about
applicability
Patient selection Was a consecutive or
random sample of
patients enrolled?
Was a case-control
design avoided?
Did the study avoid
inappropriate exclu-
sions?
Could the selection
of patients have in-
troduced bias?
Are there concerns
that the included
patients and setting
do not match the re-
view question?
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(Continued)
Yes if par-
ticipants were con-
secutively enrolled or
if all eligible partic-
ipants were enrolled
or participants were
randomly sampled.
No if participants
were selected from
those eligible.
Unclear if partici-
pant selection was not
clear from the report.
Yes if a case control
design was avoided.
Noif a case control
design was used.
Unclear if the study
design could not be
determined from the
report.
Yes
if the study avoided
inappropriate exclu-
sions (e.g. only ex-
cluded multiple preg-
nancy, congenital ab-
normalities).
No if participants
were excluded inap-
propriately (e.g. eth-
nicity, age, income).
Unclear if appropri-
ateness of exclusions
could not be assessed
from report.
Low risk if yes to all
of the signalling ques-
tions.
High or unclear risk
if “no” or “unclear”
was reported for at
least one signalling
question.
Low concern if the
sample of pregnant
women represent the
women indicated by
the review question
and if inappropri-
ate exclusions were
avoided.
High concern if the
sample of pregnant
women are different
from those indicated
in the review ques-
tion.
Unclear concern if
insufficient informa-
tion was available.
Index test -
test of placental
function
Were
the index test results
interpreted without
knowledge of the re-
sults of the reference
standard?
If a threshold was
used was it pre-spec-
ified?
Could the conduct
or interpretation of
the index test have
introduced bias?
Are there
concerns that the in-
dex test, its conduct
or its interpretation
differ from the re-
view question?
Yes if the result(s)
of the test of pla-
cental function was
interpreted without
knowledge of the ref-
erence standard.
No if the result(s) of
the test of placental
function was inter-
preted with knowl-
edge of the reference
standard.
Unclear if this was
not clear in the re-
port.
Yes if the criteria for
a positive result of
the placental func-
tion test were pre-
specified.
No if the criteria
for a positive result
were not pre-specified
or deviated from that
specified.
Unclear if this was
not clear from the re-
port.
Low risk if yes to all
of the signalling ques-
tions.
High or unclear risk
if “no” or “unclear”
was reported for at
least one signalling
question.
Low concern if the
pla-
cental function test
was performed as de-
scribed in the review
question (e.g. after 24
weeks of pregnancy to
assess placental func-
tion).
High concern if the
placen-
tal function test was
performed in a differ-
ent way to that de-
scribed in the review
question.
Unclear concern if
insufficient informa-
tion was available.
Reference standard
and target condition
Is there reference
standard likely to
correctly classify the
target condition?
Were the reference
standard results in-
terpreted
without knowledge
Could the reference
standard, its con-
duct or interpre-
tation have intro-
Are there concerns
that the target con-
dition as defined by
the reference stan-
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(Continued)
of the results of the
index test?
duced bias? dard does not match
the question?
Yes if an accept-
able reference stan-
dard was used (e.g.
SGA = birthweight
< 10th centile, Still-
birth = baby born
with no signs of life
after 24 weeks’ gesta-
tion).
No if pregnancy out-
come was not classi-
fied by an acceptable
reference standard (e.
g. low birthweight <
2.5 kg).
Unclear if this was
not clear from the re-
port.
Yes if pregnancy out-
come (live or still-
birth), and a diag-
nosis of a small for
gestational age infant
was made without
the knowledge of re-
sults of the placental
function test.
No if pregnancy out-
come and a diagno-
sis of a small for ges-
tational age infant
were made with the
knowledge of the re-
sults of the placental
function test.
Unclear if this was
not clear from the re-
port.
Low risk if yes to all
of the signalling ques-
tions.
High or unclear risk
if “no” or “unclear”
was reported for at
least one signalling
question.
Low con-
cern if acceptable ref-
erence standards were
used and if the refer-
ence standard was in-
terpreted without the
knowledge of the pla-
cental function test.
High concern if an
acceptable ref-
erence standard was
not used or the results
were interpreted with
knowledge of the re-
sult of the placental
function test.
Unclear concern if
insufficient informa-
tion was available.
Flow and Timing Was there an appro-
priate interval be-
tween the index test
and reference stan-
dard?
Did all patients re-
ceive the same refer-
ence standard?
Were all patients in-
cluded in the analy-
sis?
Could the
patient flow have in-
troduced bias?
Yes If acquisition of
the index test oc-
curred prior to birth
(reference standards
both determined af-
ter birth).
No if sample ac-
quired after deliv-
ery of the infant (i.
e. known reference
standard).
Unclear if this was
not clear from the re-
port.
Yes if all participants
had the outcome of
pregnancy and birth-
weight recorded.
No if some partici-
pants do not have the
outcome of pregnancy
and birthweight
recorded.
Unclear if this was
not clear from the re-
port.
Yes if all participants
recruited to the study
were included in the
final analysis.
No if all participants
were not included in
the final analysis.
Unclear if this was
not clear from the re-
port.
Low risk if yes to all
of the signalling ques-
tions.
High or unclear risk
if “no” or “unclear”
was reported for at
least one signalling
question.
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Appendix 4. Glossary
Fetal growth restriction (FGR) - a condition where a fetus fails to attain its growth potential, i.e. is smaller than expected for its genetic
potential.
Small-for-gestational-age infant (SGA infant) - the condition where the fetal weight or birthweight is beneath a specific threshold,
generally considered to be the 10th centile.
hPL - human placental lactogen - a protein made by the trophoblast layer of the placenta.
PlGF - placental growth factor- a protein made by the trophoblast layer of the placenta.
SROC - summary receiver operator characteristic - a graphical representation of different estimates of test accuracy.
Umbilical artery Doppler - a measurement of fetal blood flow through the umbilical artery using Doppler ultrasound
Uterine artery Doppler - a measurement of maternal blood flow through the uterine artery using Doppler ultrasound
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